Coivas Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8/10
Best for: all-inclusive compounded GLP-1 pricing with a money-back guarantee
Price is where Coivas scores best in our breakdown.
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
Coivas is an all-inclusive GLP-1 telehealth service operated by WellVi LLC (d/b/a Coivas) with prescriptions through Arora Health & Aesthetics, LLC. It offers compounded semaglutide from $149/mo and compounded tirzepatide from $229/mo on a quarterly plan (or $179/$289 monthly), with one price covering the doctor consult, prescription, shipping and support. Available in all 50 states, with a money-back guarantee.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Vetted alternatives to Coivas
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Coivas at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $149/mo (Compounded Semaglutide Quarterly $149/mo (Monthly $179/mo) verified on coivas.com 2026-06-19; one price includes consult, Rx, shipping & support)
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How we scored Coivas
Each dimension is scored algorithmically from Coivas’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
8.5/10At $149/mo, Coivas runs about 12% below the $169 median for GLP-1 providers.
Effectiveness25%
8.5/10Coivas offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.8/10Online intake and platform experience — consult included in the price; 6 platform features disclosed.
Trust & Safety15%
8.4/10Core details confirmed by our editors; no FDA warning letters on file; dispenses through an accredited compounding pharmacy (last checked 2026-08-02).
Accessibility10%
6.5/10Coivas's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
6.3/10Coivas provides standard clinician follow-up; no extended coaching or community program is disclosed.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this Coivas review
Last checked August 2026- Confirmed current pricing across 2 dose/plan tiers
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
What to expect when you sign up with Coivas
We walked Coivas’s public signup flow in July 2026 to document the process — the steps, pricing transparency, and what’s required — before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Complete an online health questionnaire in about 5 minutes.
- 2A licensed provider reviews your profile and issues a prescription, often in under a day.
- 3When required by state law, the provider performs a video or phone consultation.
- 4If approved, medication ships from a licensed pharmacy with free 2-day delivery.
- New-user monthly prices are shown up front: Semaglutide $119/mo quarterly ($129 monthly), Tirzepatide $199/mo quarterly ($229 monthly); prices increase for existing GLP-1 users and after the first cycle.
- HSA/FSA eligible and available in all 50 states.
- Advertises 24/7 access with expert consultations at no extra cost and anytime clinician messaging via the member portal.
- A video/phone consult is described as occurring only when required by state law, not universally.
- Claims most patients are approved in under 2 hours.
Coivas customer support
GLP-1 medications Coivas offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
Prices re-verified
Compounded Semaglutide Quarterly $149/mo (Monthly $179/mo) verified on coivas.com 2026-06-19; one price includes consult, Rx, shipping & support
Compounded Tirzepatide Quarterly $229/mo (Monthly $289/mo) verified on coivas.com 2026-06-19
Ready to get started?
Plans and promotions change often — check Coivas's current pricing and active discounts before you decide.
What we like
- All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
- Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
- Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
- Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
- Most patients approved in under 2 hours; refund if no provider visit or prescription occurs
Watch-outs
- Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
- Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
- Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
- No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
Is Coivas worth it? Our verdict
Coivas positions itself around one thing: all-inclusive compounded GLP-1 pricing with a money-back guarantee. It runs $149/month — toward the affordable end of the market.
Coivas rounds out its offering with All-Inclusive Price and Money-Back Guarantee.
How much Coivas actually costs
- Compounded semaglutide — $149/month
- Compounded tirzepatide — $229/month
That puts Coivas below the roughly $169 median ongoing price across the GLP-1 providers we track — a real cost advantage.
Found (about $149/month) is one of the closest alternatives to weigh Coivas against.
Medications: what Coivas prescribes
Coivas prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two most-studied weight-loss molecules on the market today. These are dispensed as compounded formulations from a licensed pharmacy, which is how the price stays below brand-name pens. Compounded drugs aren't FDA-approved as finished products — the standard trade-off across the compounded-GLP-1 market.
Who Coivas is best for — and who should skip it
A good fit if you…
- are focused on the lowest ongoing monthly cost.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
Coivas dispenses through an accredited compounding pharmacy. We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
Coivas earns its place on the shortlist mainly on price: at $149/month it's one of the more affordable ways to stay on a GLP-1, without obvious corners cut on access or oversight.
The Bottom Line
Price is where Coivas scores best in our breakdown.
Ready to start with Coivas?
Starting at $149/month. See current pricing and start your free consultation.
Coivas might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
- If you want brand-name Ozempic, Wegovy, Mounjaro or Zepbound, consider GobyMeds.
- If the lowest possible monthly price is your top priority, consider Sesame Care (from $59/mo).
- If you want built-in coaching and behavior-change support, consider ShedRx.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this Coivas review:
Sources & methodology — as of August 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Coivas's current pricing
Plans start at $149/month. Start your free consultation to check eligibility and today's price.